BioNTech Investor Day Presentation Deck
BNT151
Therapeutic activity of BNT151 in combination with T cell vaccination
Substantial improvement of the therapeutic efficacy of RNA-LPX vaccination by BNT151
Day 0
8
+
↑
↑ Treatment
↑Immunophenotyping (blood)
B16F10 s.c. tumor
Vaccine target: TRP1
(differentiation antigen containing a
CD8 T-cell epitope)
Tumor size (mm³)
C57BL/6
128-
64-
15 22 29 100
+ +
11 ↑ ↑
2048 0/11 CR
1024-
512-
256
32
16
8
4
2
0
Vaccine alone
20
40 60
Days after tumor inoculation
80
Per cent of CD8+ T cells
TRP1 specific CD8+ T cells
40
30
0
Vaccine: +
h|L2:
BNT151:
****
ns
+
Vaccine + hIL-2
7/11 CR
0 20 40 60
Days after tumor inoculation
80
CD8+ to Treg ratio
40
0
Vaccine:
hlL2:
BNT151:
10-
CD8+ to Treg ratio
On
+
****
ns
11/11: CR
Median tumor size (mm³)
1750
1500-
1250-
1000-
750-
500
250-
Vaccine + BNT151
1 Kranz LM, et al. SITC Annual Meeting 2019; Poster presentation 620; 2 Kranz LM, et al. CIMT Annual Meeting 2021; ePresentation.
Vormehr M, et al. SITC Annual Meeting 2019; Poster presentation 626.
0 20 40 60
Days after tumor inoculation
80
0
0
25
50
Days after tumor inoculation
75
NUM
RiboCytokines
Control
TRP1 vaccine + Control
Control + hlL2
- Control + BNT151 ***
→TRP1 vaccine + hlL2 ****
TRP1 vaccine + BNT151 ****
Days of treatment
***
**
BIONTECH
148View entire presentation